Israeli artificial intelligence (AI) peptide drug discovery company Pepticom announced today that it has raised $5 million in a Series A financing round from the Chartered Group. The Jerusalem-based company's AI technology streamlines and significantly accelerates the ability of researchers to discover advanced peptide-based drug candidates. Peptides are used in various therapies, and are recognized for being highly selective and efficacious as well as relatively safe. The pharma industry has recently shown an increased interest in peptide research and development, leading to a resurgence of peptide drug candidates. The process of discovering new peptides with lifesaving potential, however, is still costly and time consuming.